Oxelumab
Modify Date: 2023-01-16 10:26:04
Oxelumab structure
|
Common Name | Oxelumab | ||
|---|---|---|---|---|
| CAS Number | 1186098-83-8 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of OxelumabOxelumab (R 4930) is a human monoclonal antibody against the OX40 ligand (OX40L). Oxelumab can be used for the research of asthma[1]. |
| Name | Oxelumab |
|---|
| Description | Oxelumab (R 4930) is a human monoclonal antibody against the OX40 ligand (OX40L). Oxelumab can be used for the research of asthma[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Oxelumab (10 μg/mL; 3 d) represses cell proliferation of NK cells[2]. Cell Proliferation Assay[2] Cell Line: Natural Killer (NK) cell lines Concentration: 10 μg/mL Incubation Time: 3 days Result: Inhibited cell proliferation of NK cells. |
| In Vivo | Oxelumab (5 and 30 mg/kg; i.p., once daily for twice) affects the concentrations of IL-6 and the frequencies of splenic human effector memory T cells and switched B cells[1]. Animal Model: NSG mice with PBMCs from UC patients with simple clinical colitis activity index (SCCAI)[1] Dosage: 5 and 30 mg/kg Administration: Intraperitoneal injectionon; 5 and 30 mg/kg, once daily, on days 6 and 13 Result: Reversed the ethanol-induced colon dilated and the lost of distinct pattern of pellets. Decreased the level of IL-6 and increased the concentrations of glutamic acid. Reduced frequencies of splenic human effector memory T cells and switched B cells. |
| References |
| No Any Chemical & Physical Properties |